Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary new platform.
All the latest company news, press releases and updates from Epitopea.

Epitopea Featured in BioWorld

May 11, 2022

Epitopea closes $14M seed round for tumor antigen discovery

Epitopea Ltd. raised $13.6 million in seed financing to take forward a new cancer immunotherapy platform based on the identification of a new class of tumor-specific antigens encoded by non-canonical genomic sequences.

The Cambridge, U.K.-based firm is building on the academic research of company co-founders Claude Perrault and Pierre Thibault, both based at the Institute for Research in Immunology and Cancer at the Université de Montréal. In a series of papers, Perrault, Thibault, and colleagues have described novel tumor antigens encoded by what were previously considered non-coding gene sequences, including long-noncoding RNAs, short open reading frames and pseudogenes.

To read the full article click here (PDF, opens in new tab).

Related News

Revealing the true targets for next generation immunotherapies
© 2022 Epitopea Ltd | All Rights Reserved
Created by FDM Digital
arrow-down